Conflict of interest statement: The authors declare no conflict of interest.193. J Clin Oncol. 2018 May 1;36(13):1308-1316. doi: 10.1200/JCO.2017.75.9175. Epub2018 Mar 15.Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib inPatients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).Untch M(1), von Minckwitz G(1), Gerber B(1), Schem C(1), Rezai M(1), FaschingPA(1), Tesch H(1), Eggemann H(1), Hanusch C(1), Huober J(1), Solbach C(1),Jackisch C(1), Kunz G(1), Blohmer JU(1), Hauschild M(1), Fehm T(1), NekljudovaV(1), Loibl S(1); GBG and the AGO-B Study Group.Author information: (1)Michael Untch, Helios-Klinikum, Berlin-Buch; Jens-Uwe Blohmer, St GertraudenKrankenhaus, Berlin; Gunter von Minckwitz, Valentina Nekljudova, and SibylleLoibl, German Breast Group, Neu-Isenburg; Bernd Gerber,Universitäts-Frauenklinik, Rostock; Christian Schem, Mammazentrum am Krankenhaus Jerusalem, Hamburg; Mahdi Rezai, Luisenkrankenhaus; Tanja Fehm,Universitäts-Frauenklinik, Düsseldorf; Peter A. Fasching, UniversitätsklinikumErlangen, Erlangen; Hans Tesch, Hämatologisch-Onkologische Gemeinschaftspraxis amAgaplesion Bethanien Krankenhaus; Christine Solbach, Universitäts-Klinikum,Frankfurt; Holm Eggemann, Universitäts-Frauenklinik, Magdeburg; Claus Hanusch,Klinikum zum Roten Kreuz, München; Christian Jackisch, Sana Klinikum Offenbach,Offenbach am Main; Georg Kunz, Klinik für Gynäkologie und Geburtshilfe, Dortmund;Maik Hauschild, Gesundheitszentrum Fricktal, Rheinfelden; and Jens Huober, Klinikfür Frauenheilkunde und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany.Purpose The GeparQuinto phase III trial demonstrated a lower pathologic complete response (pCR; pT0 ypN0) rate when lapatinib was added to standardanthracycline-taxane chemotherapy compared with trastuzumab in patients withhuman epidermal growth factor receptor 2 (HER2) -positive breast cancer. Here, wereport the long-term outcomes. Methods Patients with HER2-positive tumors (n =615) received neoadjuvant treatment with epirubicin (E) plus cyclophosphamide(C), followed by docetaxel (T) in combination with either lapatinib (L) ortrastuzumab (H; ECH-TH arm: n = 307; ECL-TL arm: n = 308). All patients received adjuvant trastuzumab for a total of 12 months and 18 months in the ECH-TH andECL-TL arms, respectively. Median follow-up was 55 months. Results Three-yeardisease-free survival (DFS), distant DFS (DDFS), and overall survival (OS) werenot significantly different between the two treatment arms. Long-term outcomescorrelated with pCR (DFS: hazard ratio [HR], 0.63; P = .042; DDFS: HR, 0.55; P = .021; and OS: HR, 0.31; P = .004). A benefit only for OS was observed in patientswho were treated with trastuzumab and achieved pCR versus no pCR (HR, 0.15; P =.010), whereas no difference was found in patients with pCR versus without pCR inthe lapatinib arm. DFS and DDFS remained unchanged in both treatment armsaccording to hormone receptor status, whereas OS was significantly better inhormone receptor-positive patients who were treated with neoadjuvant lapatinib(HR, 0.32; P = .019), followed by adjuvant trastuzumab. No difference wasobserved in hormone receptor-negative patients; however, the small number ofevents limits this interpretation. Within the hormone receptor-negative cohort,pCR was significantly associated with DFS, DDFS, and OS ( P = .002, .005, and.002, respectively). Conclusion pCR correlated with long-term outcome. Inpatients with hormone receptor-positive tumors, prolonged anti-HER2treatment-neoadjuvant lapatinib for 6 months, followed by adjuvant trastuzumabfor 12 months-significantly improved survival compared with anti-HER2 treatmentwith trastuzumab alone.DOI: 10.1200/JCO.2017.75.9175 PMID: 29543566 